Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 470-476 , November 2007

18F-Fluoroestradiol

  • Lavanya Sundararajan, MD

      Affiliations

    • Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA.
    • ,
  • Hannah M. Linden, MD

      Affiliations

    • Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA.
    • ,
  • Jeanne M. Link, PhD

      Affiliations

    • Division of Nuclear Medicine, University of Washington, Seattle, WA.
    • ,
  • Kenneth A. Krohn, PhD

      Affiliations

    • Division of Nuclear Medicine, University of Washington, Seattle, WA.
    • ,
  • David A. Mankoff, MD, PhD

      Affiliations

    • Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA.
    • Division of Nuclear Medicine, University of Washington, Seattle, WA.
    • Corresponding Author InformationAddress reprint requests to David A. Mankoff, MD, PhD, Radiology Mail Stop G2-600, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Seattle, WA 98109.

References 

  1. Pujol P, Hilsenbeck SG, Chamness GC, et al. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994;74:1601–1606
  2. Osborne CK, Yochmowitz MG, Knight WA, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46(suppl 12):2884–2888
  3. Bloom ND, Tobin EH, Schreibman B, et al. The role of progesterone receptors in the management of advanced breast cancer. Cancer. 1980;45:2992–2997
  4. Briasoulis E, Karavasilis V, Kostadima L, et al. Metastatic breast carcinoma confined to bone: Portrait of a clinical entity. Cancer. 2004;101:1524–1528
  5. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001;19:3357–3366
  6. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596–2606
  7. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial Arimidex Study Group. J Clin Oncol. 2000;18:3758–3767
  8. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584–2589
  9. Spataro V, Price K, Goldhirsch A, et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance (The International Breast Cancer Study Group (formerly Ludwig Group)). Ann Oncol. 1992;3:733–740
  10. Hull D, Clark G, Osborne C, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983;43:413–416
  11. Mankoff DA, Deshdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2000;2:71–88
  12. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17:1573–1576
  13. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212–1221
  14. VanBrocklin HF, Pomper MG, Carlson KE, et al. Preparation and evaluation of 17-ethynyl-substituted 16 alpha-[18F]fluoroestradiols: Selective receptor-based PET imaging agents. Int J Rad Appl Instrum B. 1992;19:363–374
  15. Landvatter SW, Kiesewetter DO, Kilbourn MR, et al. (2R*, 3S*)-1-[18F]fluoro-2,3-bis(4-hydroxyphenyl)pentane [(18F]fluoronor-hexestrol), a positron-emitting estrogen that shows highly-selective, receptor-mediated uptake by target tissues in vivo. Life Sci. 1983;33:1933–1938
  16. Seimbille Y, Benard F, Rousseau J, et al. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol. 2004;31:691–698
  17. Seimbille Y, Rousseau J, Benard F, et al. 18F-labeled difluoroestradiols: Preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids. 2002;67:765–775
  18. Cummins CH. Radiolabeled steroidal estrogens in cancer research. Steroids. 1993;58:245–259
  19. Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med. 1998;42:8–17
  20. Jonson SD, Bonasera TA, Dehdashti F, et al. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol. 1999;26:123–130
  21. Petra PH. The plasma sex steroid binding protein (SBP or SHBG) (A critical review of recent developments on the structure, molecular biology and function). J Steroid Biochem Mol Biol. 1991;40:735–753
  22. Aliaga A, Rousseau JA, Cadorette J, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol. 2007;9:144–150
  23. Aliaga A, Rousseau JA, Ouellette R, et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol. 2004;31:761–770
  24. Seo JW, Comninos JS, Chi DY, et al. Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: Synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006;49:2496–2511
  25. Brodack JW, Kilbourn MR, Welch MJ, et al. Application of robotics to radiopharmaceutical preparation: controlled synthesis of fluorine-18 16 alpha-fluoroestradiol-17 beta. J Nucl Med. 1986;27:714–721
  26. Lim JL, Zheng L, Berridge MS, et al. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16alpha-fluoroestradiol. Nucl Med Biol. 1996;23:911–915
  27. Romer J, Fuchtner F, Steinbach J, et al. Automated synthesis of 16alpha-[18F]fluoroestradiol-3,17beta-disulphamate. Appl Radiat Isot. 2001;55:631–639
  28. Tewson TJ, Mankoff DA, Peterson LM, et al. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999;26:905–913
  29. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol. 1997;24:341–348
  30. Mathias CJ, Welch MJ, Katzenellenbogen JA, et al. Characterization of the uptake of 16 alpha-([18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum. 1987;14:15–25
  31. Moresco RM, Casati R, Lucignani G, et al. Systemic and cerebral kinetics of 16 alpha [18F]fluoro-17 beta-estradiol: A ligand for the in vivo assessment of estrogen receptor binding parameters. J Cereb Blood Flow Metab. 1995;15:301–311
  32. Moresco RM, Scheithauer BW, Lucignani G, et al. Oestrogen receptors in meningiomas: A correlative PET and immunohistochemical study. Nucl Med Commun. 1997;18:606–615
  33. Mankoff DA, Peterson LM, Tewson TJ, et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001;42:679–684
  34. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–56
  35. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766–1774
  36. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793–2799
  37. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45–48
  38. Mankoff DA, Peterson LM, Petra PH, et al. Factors affecting the level and heterogeneity of uptake [F-18] fluroestardiol [FES] in patients with estrogen receptor positive breast cancer. J Nucl Med. 2002;43:286–287
  39. McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526–1531
  40. Mortimer JE, Dehdashti F, Siegel BA, et al. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933–939
  41. Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797–2803
  42. Linden HM, Stekhova S, Link JM, et al. Understanding resistance to hormonal therapy in estrogen avid breast cancer. ASCO Proc. 2006;24(suppl):566
  43. Tsuchida T, Okazawa H, Mori T, et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET-influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol. 2007;34:205–210
  44. Yoshida Y, Kurokawa T, Sawamura Y, et al. The positron emission tomography with 18F 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol. 2007;104:764–766
  45. Furukawa T, Lohith TG, Takamatsu S, et al. Potential of the FES-hERL PET reporter gene system—basic evaluation for gene therapy monitoring. Nucl Med Biol. 2006;33:145–151
  46. Takamatsu S, Furukawa T, Mori T, et al. Noninvasive imaging of transplanted living functional cells transfected with a reporter estrogen receptor gene. Nucl Med Biol. 2005;32:821–829

 Supported in part by NIH Grants CA42045 and CA72064.

PII: S0001-2998(07)00087-6

doi: 10.1053/j.semnuclmed.2007.08.003

Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 470-476 , November 2007

Article Tools

* Image Usage & Resolution